FairValu
BETA
BOSTON SCIENTIFIC CORP

BOSTON SCIENTIFIC CORP

BSX

Medical Devices • Healthcare

Current Price
$50.460.00%
Market Cap
$75.00B
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

AI Analysis of BSX's Strategic Position

Access detailed SWOT, moat analysis, growth sustainability, and risk assessment powered by Vertex AI.

Summary

Multi-agent institutional research for BSX

Factor Scorecard

Factor scores will populate once the financial statement data finishes loading.

Price Chart

BSX via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available from current approved sources.

No Data

No annual financial data available.

Analyst Consensus

0 Analysts
Recommendation mix unavailable from the current feed
Buy
-
Hold
-
Sell
-

Coverage count comes from 0 analyst opinions, but the Buy/Hold/Sell mix was not included in the current payload.

Price Target

N/AAverage Target
Low
N/A
Current
$50.46
High
N/A

Peer Comparison

TickerPrice
BSXBOSTON SCIENTIFIC CORP
$50.46
Financial data not available for quantitative analysis.
Company News & Profile

Loading latest news...

About the Company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Next Earnings Date

Jul 29, 2026